RESEARCH ARTICLE

TLR Agonist Augments Prophylactic Potential of Acid Inducible Antigen Rv3203 against *Mycobacterium tuberculosis* H37Rv in Experimental Animals

Owais Mohammad1*, Jagdeep Kaur2*, Gurpreet Singh2*, Syed Mohd Faisal1, Asim Azhar1, Mohd Ahmar Rafa1, Umesh Dutt Gupta3, Pushpa Gupta3, Rahul Pal4, Swaleha Zubair5*

1 Molecular Immunology Laboratory, Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India, 2 Department of Biotechnology, Panjab University, Chandigarh, India, 3 National JALMA Institute for Leprosy & other Mycobacterial Diseases, Tajganj, Agra, India, 4 National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India, 5 Women’s College, Aligarh Muslim University, Aligarh, India

* These authors contributed equally to this work.

swalehazubair@yahoo.com (SZ); owais_lakhnawi@yahoo.com (OM)

Abstract

In general, the members of Lip gene family of *Mycobacterium tuberculosis* evoke strong immune response in the host. Keeping this fact into consideration, we investigated role of Rv3203, a cell wall associated protein with lipolytic activity, in imparting protection against experimental murine tuberculosis. The data of the present study suggested that archaeosome encapsulated Rv3203 induce strong lymphocyte proliferation, up-regulated Th-1 biased cytokines profile, increased expression of co-stimulatory markers on both antigen presenting cells and T lymphocytes. The immuno-prophylactic response was further modulated by exposure of the animals to zymosan, a TLR2/6 agonist, prior to immunization with archaeosome encapsulated Rv3203. Interestingly, pre-treatment of experimental animals with zymosan boosted strong immunological memory as compared to archaeosome encapsulated Rv3203 as well as BCG vaccine. We conclude that priming of immunized animal with TLR agonist followed by immunization with archaeosomes encapsulated Rv3203 offer substantial protection against tuberculosis infection and could be a potential subunit vaccine based prophylactic strategy.

Introduction

The pathogen *Mycobacterium tuberculosis* (*M. tuberculosis*), the etiologic agent of human tuberculosis (TB), has been estimated to inflict around 9.6 million people (5.4 million men, 3.2 million women and 1.0 million children) world-wide up to the year 2014 [1–2]. Underlying these statistics is an emerging epidemic of multidrug-resistant tuberculosis (MDR-TB) and extremely drug resistance TB (XDR-TB) [1–3]. The extraordinary potential of *M. tuberculosis*
to subsist, during the hostile intracellular abode, in macrophages is generally attributed to its ability to modulate host immune responses in its favour [4]. In fact, the pathogen has acquired distinctive ability to subvert fully functioning innate and acquired immune system of the host. There has been a global effort to solve intricacies of the complex interaction between the M. tuberculosis and the host, as pathogen can also shift into a dormant non-replicating status causing a latent TB infection [5].

While immunization plays a key role in tuberculosis control programs, the success rate has been limited due to lack of efficacious vaccine [6]. The problem is further complicated by the variable efficacy of immunizations with Mycobacterium bovis bacillus Calmette-Gue´rin (BCG), the only available vaccine against tuberculosis [7, 8]. Not on a very positive note, BCG, in general, fails to induce herd immunity in a population due to limited efficacy, and also remains unsuccessful to impart long lasting memory response in the host [9]. Of late, it has been observed that BCG often fails in preventing reactivation of latent bacterium [10]. Keeping into consideration the wide spread dissemination of this important disease, it is urgent to search for novel TB vaccines and alternate immunization strategies. Interestingly, it has been found that proteins such as Ag-85, MPT-64, MPB-70, culture filtrate protein-10 (CFP-10) and early secreted antigenic target-6 (ESAT-6), are promising subunit candidates for vaccination against TB, however not as efficacious as BCG [10–14].

In silico analysis suggests that M. tuberculosis genome contains nearly 250 genes encoding putative enzymes involved in lipid metabolism [15]. In fact, most of these enzymes play crucial role in long term survival of M. tuberculosis in the host macrophages [15]. Inside host’s macrophage, bacteria start accumulating lipid in their cytoplasm to endure dormant state. The lipid droplets serve as carbon and energy source for prolonged survival in the host macrophages which led to an active Mycobacterial infection [16]. Besides lipids, lipolytic enzymes too play crucial role in the life cycle, survival and virulence of M. tuberculosis [17]. A Lip gene family in M. tuberculosis has been reported to contain 24 putative lipase/esterase (LipC to LipZ) based on the presence of the consensus sequence GXSXG characteristic of members of the α/β hydrolase-fold family [17].

It has been reported that stress-associated membrane bound antigens are potential TB vaccine candidates [18, 19]. We recently demonstrated that Rv3203 (LipV), an acid inducible protein, is a membrane bound protein [20]. Keeping this fact into consideration, we evaluated Rv3203 for its potential to activate both humoral as well as cell mediated components of the host immune system. In the next set of study, archaeosomes entrapped Rv3203 formulation was appraised for its protective efficacy against M. tuberculosis infection in mice. Zymosan, a TLR2 agonist, has been reported to be a potent adjuvant in stimulating cell mediated immune responses in the host [21]. Zymosan activates macrophages via TLR2 in collaboration with TLR6 which further modulates the immune response against the pathogens [22]. Zymosan has been reported to enhance DC maturation in vitro and stimulate production of both inflammatory and type 1 cytokines in the host [23]. Therefore in the present study we explored its capacity to collaborate with novel archaeosome based antigen delivery system to activate host immune system.

**Materials and Methods**

**Reagents**

Mycobacterium culture medium viz. Middlebrook 7H11 medium, albumin, dextrose, oleic acid, Middlebrook 7H9 broth and catalase etc. were purchased from Difco laboratories (Michigan, USA). pET expression vectors were obtained from Novagen (Darmstadt, Germany). Oligonucleotides were synthesized by BIO Serve (Hyderabad, India). Nickel (Ni/NTA) nitrilo...
acetic acid metal-affinity chromatography matrix, plasmid miniprep kit and PCR reagents were purchased from Qiagen. The rest of the reagents were of analytical grade of purity and sourced locally.

**Antibodies**

Fluorescein isothiocyanate (FITC)–conjugated rabbit anti mouse CD4 and CD8, PerCP conjugated rabbit anti mouse CD62L (MEL-14), phycoerythrin (PE)–conjugated rabbit anti mouse CD44 (IM7), anti-CD80 (B7-1) and anti-CD86 (GL1) were obtained from BD-biosciences. Commercial available kits were used for estimation of various cytokines in plasma as well as culture supernatants.

**Mice**

We used 6 to 8 weeks old female *Balb/c* mice procured from National JALMA institute for leprosy and other mycobacterial diseases, Agra, India for various immunological as well as immunoprophylactic studies.

**Ethics Statement**

All experimental procedures involving animals were approved by the Institutional Animal Ethics Committees of National JALMA institute for leprosy and other mycobacterial diseases, Tajganj, Agra, Uttar Pradesh, India. All the animal’s studies were performed under BSL-3 animal facilities, in accordance with CPCSEA (Committee for the purpose of control and supervision of experiments on animals, Govt. of India) norms. The study protocol was approved by CPCSEA, Govt of India (332/CPCSEA). All animals were observed for signs of illness, weight loss, injury, or abnormal behaviour by animal house staff twice on week days and only once on weekends. Humane painless handling of all experimental animals includes proper maintenance of living conditions and minimization of distress. The CPCSEA mandates, as formulated by institutional ethical committee, were considered throughout the experimental set up while handling the animals to minimize suffering of animals. Experimental animals were frequently managed and cared throughout the commencement of the study following acceptable standard mandates as specified by ethical committee approved by CPCSEA, Govt of India.

The animals survived after conclusion of the experiment were euthanized following humane endpoint mandates of the institutional animal ethics committee (CPCSEA, Govt of India). The euthanized animals were autoclaved followed by incineration as per the SOPs of BSL-3 lab facilities of NJIL & OMD, Agra (INDIA).

**Bacterial strains**

Both *M. tuberculosis* H37Rv strains and *M. bovis* BCG (Danish) were kind gift from Director, NJIL & OMD, Agra. *M. tuberculosis* was grown in Middlebrook 7H9 broth supplemented with OADC and also contained 0.2% glycerol and 0.05% Tween-80 [24].

**Cloning, Expression, Purification and Refolding of Rv3203**

The coding region of Rv3203 from *M. tuberculosis* H37Rv was cloned, expressed and purified as described earlier [20]. Briefly, the gene encoding Rv3203 was PCR amplified using set of primer and ligated in pQE30 vector. The ligated product was transformed in *Escherichia coli* (*E. coli*) M15 cells and screened on LB plates containing ampicillin (100μg/ml) and kanamycin (30μg/ml). For expression of recombinant Rv3203, the *E. coli* M15 cells containing pQE30-Rv3203 plasmid, were grown on LB containing ampicillin (100μg/ml) and kanamycin.
(30μg/ml). The cells were induced at A600 = 0.6 with final concentration of 0.5mM IPTG. After 3 h of induction at 37°C, cells were harvested. The recombinant Rv3203 purified from inclusion bodies in urea denatured form by Ni-NTA column chromatography. The purified Rv3203 was analyzed on 12% SDS-PAGE.

Production of rRv3203 specific polyclonal antibodies

Purified protein Rv3203 was used to raise polyclonal antibodies in rabbit. Purified protein (0.5mg) was emulsified with complete Freund’s adjuvants and injected subcutaneously. Later, three booster doses were given each at the intervals of 15 days, with purified Rv3203 protein emulsified with incomplete adjuvants. Five days after the last booster dose blood was collected and serum was isolated. The presence of antibody in serum against Rv3203 was confirmed by ELISA and Western blotting.

Culture, subcellular fractionation of M. tuberculosis H37Rv and Western blot analysis

H37Rv was grown in Middlebrook 7H9 broth base (HiMedia Laboratories Pvt. Ltd. India) supplemented with 1% glycerol and 0.05% Tween-20. An additional 2% (v/v) growth supplement OADC (BBL) was added. Details of the protocols used are provided in S1 File.

Development and characterization of archaeosomes based antigen delivery system

The membrane lipids isolated from H. Salinarum were used for preparation of archaeosomes following the method as standardized in our lab [25]. Details of the experimental procedure used are provided in the methods section of the S1 File.

Preparation of Escheriosomes

The zymosan bearing liposomes were prepared using E. coli lipid essentially by following the published procedure as standardized in our lab [26]. The details of the experimental protocol are provided in the methods section of S1 File.

Immunization schedule

The experimental animals were immunized with various in-house developed archaeosome encapsulated formulations of Rv3203 antigen. The formulations were administered at the base of the tail (lower abdominal region) of the experimental animals. Each injection corresponded to 25μg of Rv3203, keeping final volume up to 100 μl of the vehicle (lipid concentration in range of 1.5–20 μg per dose). One group of animals was pre-immunized with escheriosome encapsulated zymosan (50μg/animal) for three consecutive days viz. day−3; day−2 and day -1 prior to immunization with archaeosome encapsulated Rv3203 (day zero). The booster dosages were given on day 21 with matching formulation of antigen using the same route of administration.

Immunization studies

The details of the protocols for T cells isolation from spleens, antibody isotyping, lymphocyte proliferation, cytokine assay and FACS analysis for the expression of cell surface markers are described in S1 File. Animals were, humanely, anaesthetized with the combination of 100 mg/kg body weight of ketamine and 10mg/kg body weight of xylazine via intra-peritoneal route. The deeply sedated
animals were euthanized by cervical dislocation to perform immunological, histopathological and determination of bacterial burden in their vital organs.

**Determination of bacterial burden in vital organs after challenge with Mycobacterial infection**

The animals were divided in various experimental groups as specified in the experimental protocol. Subsequently, animals were challenged with *M. tuberculosis* H37Rv strain through aerosol route. Briefly, bacterial suspension (5×10⁷/ml) was added to the Aerosol generator device (Glas-col, USA) to inoculate each mouse with approx. 100 bacilli. Prophylactic efficacy of various in-house developed vaccines was assessed on the basis of residual *Mycobacterial* load in lungs and spleens of experimental murine tuberculosis. The follow-up study involves determination of bacterial load in the vital organs of the experimental animals (three animals from each group) on four and eight weeks post challenge with infection. Serially diluted homogenates of the various organs were plated onto 7H11 agar plates supplemented with OADC to count the viable colony-forming units in the organs of the experimental animal. In case of BCG (Danish) immunized group, thiophene carboxylic hydrazide (2mg/ml of concentration) was supplemented to prevent BCG growth and incubated for 3 weeks at 37°C. After stipulated time period, colonies were counted to assess the *Mycobacterial* load.

**Statistical analysis**

Statistical significance among experimental groups were analyzed by one way ANOVA (Holm-Sidak method) as well as Student’s *t* test using Sigma-Plot version 10.0 and 11.0 software. Differences with a *p* value (*p* ≤0.05) were considered statistically significant.

**Results**

**Purification and refolding of Rv3203**

The *Rv3203* gene from *M. tuberculosis* H37Rv was PCR amplified, cloned in pQE30 vector and transformed in *E. coli* M15. The recombinant Rv3203 was expressed as N-terminal His-tagged fusion protein and isolated as inclusions bodies. The recombinant protein was purified by affinity chromatography on Ni-NTA column. The homogeneity of recombinant Rv3203 was established on the basis of single band in SDS-PAGE (Fig 1A). The molecular weight of the recombinant Rv3203 (fused form) was found out to be around 27kDa.

**Immuno-localization of Rv3203**

Anti-rRv3203 antibody recognized purified Rv3203 as well as native Rv3203 protein in cell wall fraction of *M. tuberculosis* H37Rv. The immuno-localization result indicated that Rv3203 is a cell wall associated protein (Fig 1B). No trace of protein was observed in the culture filtrate or the cytosol fraction. The purified protein demonstrated higher molecular weight due to presence of His tag.

**Enhanced Th1 Cytokine induction in the immunized mice**

The immunogenic properties of a novel vaccine formulation is ought to be assessed on the basis of its potential to skew Th1/Th2 cytokine profile bias in the experimental animals. In general, various forms of Rv3203 based vaccine evoked robust T cell proliferation in the immunized animals in dose dependant manner (S1 Fig). Upon further evaluation of immunological outcome of novel Rv3203 based vaccine, we observed Th1 polarization in the immunized animals that were vaccinated with archae-Rv3203 as compared to the free form of Rv3203 and...
BCG (Fig 2A, 2B and 2C). There was significant up-regulation in the expression of both IL-12 and IFN-γ in the animals that were immunized with archae-Rv3203. The Th1 immune responses were more prominent in the group of animals that were pre-exposed to TLR agonist zymosan (EC-Z + archae-Rv3203).

The immunization protocol did not induce IL-4 up-regulation post immunization, however, its level increased post challenge with infection (Fig 2D). No significant expression of either Th1 or Th2 cytokines was observed in control group of animals (PBS immunization).

Archaeosome-encapsulated antigen upregulated the expression of co-stimulatory molecules

The expression profile of co-stimulatory markers was analysed on antigen presenting cells isolated from various group of immunized mice. Interestingly, immunization protocol involving archae-Rv3203 formulation was successful in up-regulating expression of CD80 (B7-1) and CD86 (B7-2) co-stimulatory molecules when compared with BCG and free form of Rv3203, on the 8th week of post challenge with M. tuberculosis infection (Fig 3). The expression level of CD80 (B7-1) and CD86 (B7-2) was more pronounced in EC-Z + archae-Rv3203 as compared to archae-Rv3203 (no-zymosan) group of animals.

Archaeosome-encapsulated Rv3203 evoked a strong memory response

After 8th week post challenge, both CD4+ and CD8+ T lymphocytes were isolated from various immunized mice groups. It has been observed that population of CD4+ and CD8+ T lymphocytes having central memory marker (CD44high and CD62Lhigh) and effector memory marker (CD44high and CD62Llow) on gated population of CD4+ and CD8+ cells got increased significantly in animal immunized with archae-Rv3203 and EC-Z+ Rv3203 when compared to BCG and free Rv3203 as shown in Fig 4. Interestingly, pre-immunization with TLR agonist induced
further increase in the population of CD4+/CD8+ T-lymphocytes with central and effector memory markers. The animals immunized with free form of antigen could not evoke significant T cell population with memory markers.

Animal protection studies

The vaccine potential of various in-house developed formulations was assessed on the basis of their ability to eliminate *Mycobacterial* burden in lungs and spleen of the experimental murine animals. As enumerated on 4th week post challenge, archae-Rv3203 vaccine formulation exhibited superior protection and caused significant reduction in *Mycobacterial* burden as compared to both free form of Rv3203 as well as BCG (**p<0.01). Animals vaccinated with archae-Rv3203 in combination with EC-Z were found to be better protected when compared to archae-Rv3203 combination and exhibited a significant reduction in *Mycobacterial* burden in various organs (Fig 5). However, on 8th week post challenge, the *Mycobacterial* load in the animal groups immunized with archae-Rv3203 alone or EC-Z + archae-Rv3203 was found out to be of the same order (Fig 5).
Discussion

Lipases are crucial for maintaining virulence and subsistence of *M. tuberculosis* in the host. In general, lipolytic enzymes carry out important physiological functions and participate in the extraordinary capacity of *M. tuberculosis* to subjugate hostile intracellular abode in the infected host [27–29]. It has been reported that Mycobacterial genes involved in lipid metabolism are up-regulated during latent phase of infection [30]. Besides RD antigens, BCG has been reported not to share dormant state antigens with *M. tuberculosis*, leading us to believe that lipases induced during latent phase, can be considered as potent targets for developing future potential vaccine candidate [31, 32].

Employing immuno-informatics analysis, Rv3203 was predicted as a cytosolic protein; however, the immune-localization studies performed with specific polyclonal antibodies suggested that the enzyme is mainly confined to the cell wall fraction of *M. tuberculosis*. The membrane bound proteins are reported to be accessible to interact with host immune system more vigorously [18]. Keeping this fact into consideration, Rv3203 was selected as contender protein to
study its potential as candidate vaccine. We have also investigated its efficacy to induce protective immunity in the immunized mice against experimental tuberculosis.

Recently, archaeosomes based antigen delivery system has been shown to induce strong cell mediated as well as humoral response against entrapped antigens in the host [33, 34]. Considering strong immune-adjuvant potential of archaeosome, we performed an extended study to correlate host immune responsiveness against a recombinant rRv3203 protein bearing archaeosome based vaccine. The novel antigen delivery system was also evaluated for its potential to impart long lasting protection against *M. tuberculosis*. As archaeosomes mediated activation of the host immune system does not involve TLR mediation, we manipulated an immunization

![Fig 4. Immunization of mice with archae-Rv3203 augments long-lasting cell memory response.](https://doi.org/10.1371/journal.pone.0152240.g004)
strategy that involved pre-immunization with TLR agonist to further activate host immune system for desirable response [35].

Lymphocyte proliferation assay revealed enhanced T cell proliferation (Rv3203 specific) with both archae-Rv3203 as well as EC-Z+ archae-Rv3203 formulation in the immunized animals (S1 Fig). The lymphocyte proliferation was considerably lesser in the animals immunized with free form of Rv3203. In a nutshell, the formidable capability of both archae-Rv3203 and EC-Z+ archae-Rv3203 formulation to induce a stable and consistent T cell activation (both CD4+/CD8+) favours its development as a new and effective vaccine candidate (S1 and S2 Figs).

Cytokine profiling further refined the notion that levels of IFN-γ and IL-12 were higher in animals primed with EC-Z+ archae-Rv3203 formulation as well as archae-Rv3203 (with no zymosan pre-treatment) (** p<0.01). Among the two immunization strategies, Th1 biased response was more prominent in animals pre-treated with TLR agonist zymosan when compared to archaeosome based Rv3203 immunization alone or free form of Rv3203. On the other hand, the Th2 cytokine expression was substantially less in the animals immunized with archaeosome based Rv3203. Moreover, Th2 cytokines also were not up-regulated in zymosan pre-treated animals (pre challenge studies).

The level of IL-4 increased in the group of mice that was immunized with various combinations such as archae-Rv3203 and EC-Z+ archae-Rv3203 post challenge with infection. This can be attributed to the fact that exposure with virulent H₃₇Rv (upon challenge) might skew immune response (Th2 type) that favours survival of pathogen in the host. Nevertheless, both archae-Rv3203 and its combination with TLR agonist were still capable of manipulating host immune response to resist pathogen survival.

As demonstrated in S3 Fig, the archae-Rv3203 and EC-Z+ archae-Rv3203 were also successful in inducing higher IgG2a versus IgG1 in the immunized experimental animals at two week PB (post booster). Further the ratios of the two antibody isotypes were increased at post
challenge in *M. tuberculosis* infection. Whereas in BCG vaccinated experimental animals, the isotype ratio was nearly similar in both PB as well as PC (post challenge) status (S3 Fig). Th1/Th2 dichotomy regulates priming of B cells for production of antibodies with IgG1 or IgG2a phenotype [36–38]. The observed antibody isotyping result indicated that archaeosomes mediated up-regulation of IFN-γ assign B cell for more IgG2a production. The data of both cytokine profiling as well as antibody isotyping suggests that EC-Z+ archae-Rv3203 form of antigen has outstanding potential to evoke Th1 type immune response in the host, essential feature for desirable prophylaxis against *M. tuberculosis*.

The zymosan based novel antigen delivery strategy show maximum up-regulation of co-stimulatory molecules on APCs of the immunized animals. This was suitably complemented with development of T cell population with CD44highCD62Lhigh as well as CD44highCD62Llow phenotype in the animals immunized with archae-Rv3203 and EC-Z+ archae-Rv3203 compared to free Rv3203 and BCG immunized groups. It has been observed that immunization schedule involving combined administration of TLR agonist and archaeosome-Rv3203 ensues in better up-regulation of memory phenotype in Rv3203 specific T cells induced in the host [39]. The central memory response accompanied with CD44highCD62Lhigh phenotype is considered to be involved in containment of secondary infection [40]. On the other hand, effector memory response accompanied with CD44highCD62Llow phenotype is reported to be enhanced during chronic infections [41, 42]. The long-lasting memory response envisages archae-Rv3203 and TLR agonist zymosan combination as an effective prophylactic approach that augments efficient interactive competence of archaeosomes with APCs, especially dendritic cells [35]. Importantly, the immune-adjuvant potential of TLR agonist zymosan combined well with archaeosome based Rv3203 vaccine to impart significant protection of immunized animals with *M. tuberculosis* challenge.

**Conclusion**

Finally, we infer that archaeosomes based Rv3203 can successfully confer long lasting and effective protection against experimental murine tuberculosis. Further, the data of the present study also suggest that immune activation as well as protection efficacy can be further enhanced by priming of animals with TLR agonist prior to immunization. Archaeosomes based Rv3203 subunit vaccine candidate in combination with TLR agonist has potential to evoke desirable immune response and elicits *Mycobacterium sps* specific T cells as well as antibodies in the host. Besides tuberculosis, the priming of TLR agonist bearing nano-vaccines may offer effective strategy for elimination of other intracellular pathogens as well.

**Supporting Information**

S1 Fig. T cell proliferation response in various immunized groups to determine the effect of dose of Rv3203 on proliferation of T lymphocytes; splenocytes, isolated from various groups of immunized BALB/c mice at two weeks post booster time point, were co-cultured in the presence of increasing amounts (1.56 to 50 μg) of Rv3203 Ag in flat-bottomed 96 well plates. After 72 h, [3H]-thymidine was added to each well and its incorporation in multiplying cells was measured after 16 h incubation with liquid scintillation counting. The accumulation of [3H] thymidine was determined in proliferating cells and denoted in term of counting per minute (CPM) values of stimulated cultures to represent Ag specific stimulation. (TIF)

S2 Fig. Proliferation of Rv3203 specific T lymphocytes isolated from immunized animals at two week post booster and also at 4 and 8 weeks post challenge upon stimulation with a fixed amount (50μg) of free Rv3203. Data represents the mean of three determinants ± S.D.
Statistical significance was determined as described in materials and methods. p < 0.01, p < 0.001 and p > 0.05 represented as (**), (***), and (NS) respectively.

S3 Fig. The sera of immunized animals were analysed for the evaluation of IgG2a: IgG1 isotypes by sandwich ELISA method. The data represent mean of three determinants ± S.D. and are representative of two different experiments with similar observation. (PB-post booster, PC-post challenge). Statistical significance was determined as described in materials and methods. p < 0.01, p < 0.001 and p > 0.05 represented as (**), (***), and (NS) respectively.

S1 File. Contains Supplementary Methods and Supplementary Results. Supplementary Methods contains following methods in detailed description (A) Culture, subcellular fractionation of M. tuberculosis H37Rv and western blot analysis, (B) Development and characterization of archaeosome based vaccine, (C) Preparation of Escheriosomes, (D) Assessment of antibody isotype in sera of experimental immunized animals, (E) Isolation of T cells from spleens of experimental immunized animals, (F) Lymphocyte proliferation assay, (G) Cell culture and cytokine assay: Determination of IFN-γ, IL-4 and IL-12, (H) Determination of cell surface markers expression as revealed by Flow cytometry. Supplementary Results contains following results in detailed description (A) ArchaeRv3203 augment the lymphocyte proliferation, (B) Archaeosome encapsulated Rv3203 evokes predominantly IgG2a and IgG2b type antibodies in the immunized mice.

Acknowledgments

The authors are thankful to the Co-ordinator, Interdisciplinary Biotechnology Unit, Aligarh Muslim University for providing the institute’s research facilities. We are also thankful to Director of National JALMA institute for leprosy and other mycobacterial diseases for providing M. tuberculosis H37Rv, BCG strain and access to the Biosafety Level 3 facility of the institute. We are thankful to Dr. Anshu Agarwal, (Professor University of California, Irvine CA 92697) for her help in critical reading, editing and language assistance of the manuscript. Syed Mohd Faisal is grateful to Department of Biotechnology, Govt. of India for granting Junior Research Fellowship (JRF). Dr. Asim Azhar acknowledges UGC, Govt of India for UGC-DS Kothari Post-Doctoral Fellowship.

Author Contributions

Conceived and designed the experiments: OM JK GS SMF SZ. Performed the experiments: GS SMF AA MAR PG. Analyzed the data: OM JK SMF RP SZ. Contributed reagents/materials/analysis tools: OM JK UDG RP SZ. Wrote the paper: OM SMF AA SZ.

References

1. World Health Organisation. “Improved data reveals higher global burden of tuberculosis”. 2014. Global Tuberculosis Report 2014.
2. World Health Organisation. 2015. Global Tuberculosis Report 2015.
3. Coker RJ Multidrug-resistant tuberculosis: public health challenges. Trop Med Int Health. 2004; 9:25–40 doi: 10.1046/j.1365-3156.2003.01155.x PMID: 14728604
4. Lin PL, Flynn JL (2010) Understanding latent tuberculosis: a moving target. J Immunol 185: 15–22. doi: 10.4049/jimmunol.0903856 PMID: 20562268
5. Garga R, Tripathia D, Kantb S, Chandrab H, Bhatnagara R and Banerjeeb N. The Conserved Hypothetical Protein Rv0574c is Required for Cell Wall Integrity, Stress Tolerance, and Virulence of Mycobacterium tuberculosis. Infect. Immun. 2015 vol. 83 no. 1 120–129.

6. Franco-Paredes C, Roupaha N, Rio CD, Santos-Preciado JI. Vaccination strategies to prevent tuberculosis in the new millennium: from BCG to new vaccine candidates. International Journal of Infectious Diseases (2006) 10, 93–102. PMID: 16377228

7. Von-Reyn CF, Vuola JM. New vaccines for the prevention of tuberculosis. Clin Infect Dis. 2002; 35: 465. PMID: 12145732

8. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995; 346: 1339–1345. PMID: 7475776

9. Sepulveda RL, Parcha C, Sorensen RU. Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile. Tuber Lung Dis. 1992; 73:372–377. PMID: 1292719

10. Bosio CM, Orme IM. Effective, non-sensitizing vaccination with culture filtrate proteins against virulent Mycobacterium bovis infections in mice. Infect Immun. 1998; 66:5048–5051. PMID: 9746617

11. Keyser A, Troud JM, Taylor JL, Izzo AA. BCG sub-strains induce variable protection against virulent pulmonary Mycobacterium tuberculosis infection, with the capacity to drive Th2 immunity. Vaccine. 29 (2011) 9308–9315. doi: 10.1016/j.vaccine.2011.10.019 PMID: 22015391

12. Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, Rhoades ER, et al. Long-term Efficacy of BCG Vaccine in American Indians and Alaska Natives. JAMA. 2004; 291:2086–2091. PMID: 15126436

13. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomized, placebo-controlled phase 2b trial. Lancer 2013: 381: 1021–28. doi: 23931465

14. Al-Attiyah R, Mustafa AS, Abal AT, El-Shamy AS, Dalemans W, Skeiky YA. In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. ClinExpt Immunol. 2004; 138:139–144.

15. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998; 393:537–544.

16. McKinney JD, Honerzu Bentrup K, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme iso-citrate lase. Nature. 2000; 406: 735–738. PMID: 10963599

17. Dedieu L, Serveau-Avesque C, Kremer L, Canaan S. Mycobacterial lipolytic enzymes: A gold mine for tuberculosis research. Biochimie. 2013; 95(1):66–73. doi: 10.1016/j.bioch.2012.07.008 PMID: 22819994

18. Singh S, Sarava S, Sharma I. Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis. Vaccine 32 (2014) 712–716. doi: 10.1016/j.vaccine.2013.11.065 PMID: 24300592

19. Canaan S, Maurin D, Chahianian H, Pouilly B, Durossseau C, Frassinetti F, et al. Expression and characterization of the protein Rv1399c from mycobacterium tuberculosis. Eur. J. Biochem. 2004; 271:3953–3961.

20. Singh G, Arya S, Narang D, Jadeja D, Singh G, Gupta UD, et al. Characterization of an acid inducible lipase Rv3203 from Mycobacterium tuberculosis H37Rv. MolBiol Rep. 2014; 41:285–296.

21. Sato Morihito, Sano Hitomi, Iwaki Daisuke, Kudo Kazumi, Konishi Masanori, Takahashi Hiroki, et al. Direct Binding of Toll-Like Receptor 2 to Zymosan, and Zymosan-Induced NF-κb Activation and TNF-α Secretion Are Down-Regulated by Lung Collectin Surfactant Protein A. J. Immunol.2003; 171:417–425. PMID: 12817025

22. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med. 2003; 197(9):1107–17. PMID: 12719479

23. Olivier A, Sainz-Perez A, Hong H, Sparwasser T, Majlessi L, Leclerc C. The adjuvant effect of TLR agonists on CD4+ effector T cells is under the indirect control of regulatory T cells. Eur J Immunol. 2011; 41 (8):2303–2013. doi: 10.1002/eji.201041387 PMID: 21538349

24. Petricevic VL, Ueda C, Alves RCB, da Silva MA, Moreno C, Meio AR, et al. A single strain of Mycobacterium bovis bacillus Calmette-Guérin (BCG) grown in two different media evokes distinct immunologic immune responses in mice. Braz J Med Biol Res 34(1) 2001.

25. Sheikh MA, Hasan I, Khan U, Owais M. Fusogenic potential of sperm membrane lipids: Nature’s wisdom to accomplish targeted gene delivery. FEBS letters 2006; 580 (9), 2183–2190. PMID: 16580670
26. Ahmad E, Fatima MT, Saleemuddin M, Owais M. Plasma beads loaded with Candida albicans cytosolic proteins impart protection against the fungal infection in BALB/c mice. Vaccine 2012; 30 (48), 6851–6858. doi: 10.1016/j.vaccine.2012.09.010 PMID: 23044405

27. Getzoff ED, Tainer JA, Lerner RA, Geysen HM. The chemistry and mechanism of antibody binding to protein antigens. Adv Immunol.1988; 43:1–98.

28. Milich DR. Synthetic T and B cell recognition sites: implications for vaccine development. Adv Immunol.1989; 45:195–282.

29. Brust B, Lecoufle M, Tuallon E, Dedieu L, canaan S, Valverde V, et al. Mycobacterium tuberculosis lipolytic enzymes as potential biomarkers for the diagnosis of active tuberculosis. PLOS One. 2011; 6(9): e25078. doi: 10.1371/journal.pone.0025078 PMID: 21966416

30. Deb C, Daniel J, Sirakova TD, Abomoelak B, Dubey VS, Kolattukudy PE. A novel lipase belonging to the hormone-sensitive lipase family induced under starvation to utilize stored triacylglycerol in Mycobacterium tuberculosis. J Biol Chem. 2006; 281:3866–3875. PMID: 16354661

31. Shanahan ER, Pinto R, Triccas JA, Britton WJ, West NP. Cutinase-like protein-6 of Mycobacterium tuberculosis is recognized in tuberculosis patients and protects mice against pulmonary infection as a single and fusion protein vaccine. Vaccine.2010; 28:1341–1346. PMID: 19941992

32. Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KL, et al. Immunogenicity of Eight Dormancy Regulon-Encoded Proteins of Mycobacterium tuberculosis in DNA-Vaccinated and Tuberculosis-Infected Mice. Infect. Immun., Feb. 2007, p. 941–949 PMID: 17145953

33. Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine. 2007; 25:3742–3751. PMID: 17321015

34. Ansari MA, Zubair S, Mahmood A, Gupta P, Khan AA, Gupta UD, et al. RD antigen based nanovaccine imparts long term protection by inducing memory response against experimental murine tuberculosis. PLOS One. 201; 6:e22889. doi: 10.1371/journal.pone.0022889 PMID: 21853054

35. Mairaj AA, Zubair S, Tufail S, Ahmad E, Khan MR, Quadri Z, et al. Ether lipid vesicle-based antigens impart protection against experimental listeriosis. International journal of nanomedicine, 2012; 7, 2433–2447. PMID: 22745536

36. Arlehamn CSL, Sidney J, Henderson R, Greenbaum JA, James EA, Moutafsi M, et al. Dissecting mechanism of Immunodominance to the common tuberculosis antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7) and Rv1038c (EsxJ). J Immunol.2012; 188:5020–5031. doi: 10.4049/jimmunol.1103556 PMID: 22504645

37. Garcia-Pelayo MC, Bachy VS, Kaveh DA, Hogarth PJ. BALB/c mice display more enhanced BCG vaccine induced Th1 and Th17 response than C57BL/6 mice but have equivalent protection. Tuberculosis 95 (2015) 48–53. doi: 10.1016/j.tube.2014.10.012 PMID: 25467292

38. Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity.1996; 5:285–293. PMID: 8808683

39. Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol.1998; 16:201–223. PMID: 9597129

40. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Anita R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol.2003; 4:225–234. PMID: 12563257

41. Appay V, Dunbar PR, Callan M, Kienemann P, Gillespie GM, Papagno L, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med.2002; 8:379–385. PMID: 11927944

42. Champagne P, Ogg GS, King AS, Knabenbauer C, Ellefsen K, Nobile M, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature.2001; 410:106–111. PMID: 11242051